Can a GLP-1 help with weight gain after menopause?

Dr. Linda's take

If the number on the scale started climbing after your periods stopped for good, and your usual habits are not touching it, you are not imagining things and you did not do anything wrong. Weight and body shape genuinely shift after menopause, and the change is biological, not a question of willpower. A lot of the coverage online blurs perimenopause and postmenopause together, but they are not the same phase, and this piece is specifically about what happens after menopause, once estrogen has settled at a lower level. My goal is not to tell you what to take. It is to lay out what the research actually shows about why this happens and what these medications do and do not do, so that a conversation with your clinician starts from information rather than from marketing.

Why does weight, and especially belly fat, shift after menopause?

Estrogen helps steer where the body stores fat. Before menopause, estrogen promotes the accumulation of subcutaneous fat, the kind that sits under the skin on the hips and thighs. After the menopausal transition, the drop in estrogen instead favors the accumulation of central body fat, the deeper abdominal or visceral fat that wraps around the organs. This is part of why waistlines can thicken even when overall weight barely moves.

The scale of that shift is measurable. On average, visceral fat rises from roughly 5% to 8% of total body fat before menopause to about 15% to 20% of total body fat after menopause. Researchers who have tracked women through this window describe an acceleration of fat gain and a decline in lean mass during the menopausal transition, and they note that these changes appear to be driven by the transition itself and not simply by getting older. Naming that is its own kind of relief, because the goalposts really did move, and understanding why is the first step toward deciding what to do about it. If you want the earlier side of this story, we cover why perimenopause weight gain happens separately.

What are GLP-1 medications, and how do they support weight management?

GLP-1 receptor agonists are a class of medicines that act on a natural gut hormone pathway involved in appetite and blood sugar regulation. Semaglutide is a GLP-1 analogue that selectively binds to and activates the GLP-1 receptor. Tirzepatide works on two receptors at once, acting as both a GIP receptor and a GLP-1 receptor agonist. By acting on the systems that regulate appetite and fullness, these medicines can make it easier to eat less without fighting constant hunger.

Both are FDA-approved for chronic weight management. Semaglutide, marketed for weight management as Wegovy, is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight who also have at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. Tirzepatide, marketed for weight management as Zepbound, carries a comparable indication for adults with obesity or with overweight and a weight-related condition. Neither approval is specific to menopause, and menopausal status is not part of the labeled indication.

What does the trial evidence show for weight management?

The largest trials were not limited to postmenopausal women, but they enrolled broad adult populations that included many women past menopause. In the STEP 1 trial, adults with overweight or obesity and without diabetes took once-weekly semaglutide 2.4 mg or placebo for 68 weeks. Average body weight fell by 14.9% with semaglutide compared with 2.4% with placebo, and 86.4% of the semaglutide group lost at least 5% of their body weight. Tirzepatide was tested in the SURMOUNT-1 trial, in which adults with obesity or overweight and without diabetes received the medication or placebo for 72 weeks. Average body weight fell by 20.9% at the highest 15 mg dose, compared with 3.1% with placebo. These are averages from controlled trials that paired the medication with lifestyle change, and individual results vary. They describe what happened across a group, not a promise for any one person.

What about muscle and lean mass?

Weight loss from almost any method, including this medication class, is not purely fat. Some of it comes from lean mass, which includes muscle. In the body-composition substudy of the STEP 1 trial, about 40% of the weight lost on semaglutide was lean soft tissue, and in the SURMOUNT-1 substudy the corresponding figure for tirzepatide was about 26%. That matters more after menopause, precisely because lean mass is already declining across this stage of life. We go deeper into this in our guide on muscle loss and these medications in perimenopause, so I will not repeat it here, except to note that resistance exercise and adequate protein intake are the levers most often studied to help preserve muscle during weight loss, and they are worth raising with your clinician up front.

What are the safety considerations?

Both medications carry a boxed warning, which is the strongest warning the FDA uses. In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, and whether it does the same in humans is not known. The tirzepatide label carries the same boxed warning about thyroid C-cell tumors seen in rats. Because of this, both medications are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. These are not medicines to start without a clinician who knows your personal and family history, including your thyroid history.

None of this rules these medications in or out for you. It is the context a licensed clinician needs in order to decide, with you, whether this class fits your health, your history, and your goals.

What should you ask your clinician?

If you want a structured way to begin that conversation, Body Good Studio's quiz is built to map your symptoms to a starting point before you talk with a clinician.

Frequently asked questions

Is weight gain after menopause really different from before?

The pattern changes, not just the amount. As estrogen falls after menopause, fat storage shifts toward the abdomen, and visceral fat rises from roughly 5% to 8% of total body fat before menopause to about 15% to 20% of total body fat after menopause. That is why the middle can thicken even when your habits have not changed.

Are GLP-1 medications approved specifically for menopausal weight gain?

No. Semaglutide and tirzepatide are FDA-approved for chronic weight management in adults who meet weight and comorbidity criteria, not for menopause specifically. Menopausal status is not part of the labeled indication, so any use framed around menopause is a conversation to have with a clinician.

How much weight did people lose in the trials?

In the STEP 1 trial, average body weight fell by 14.9% with once-weekly semaglutide 2.4 mg compared with 2.4% with placebo over 68 weeks. In the SURMOUNT-1 trial, average body weight fell by 20.9% at the highest 15 mg dose of tirzepatide compared with 3.1% with placebo over 72 weeks. These are group averages from trials that were not limited to postmenopausal women, so individual results vary.

Will I lose muscle on a GLP-1?

Some of the weight lost on these medications is lean mass rather than fat. In the STEP 1 body-composition substudy, about 40% of the weight lost on semaglutide was lean soft tissue, and in the SURMOUNT-1 substudy the figure for tirzepatide was about 26%. Resistance exercise and adequate protein are the levers most often studied to help protect muscle, which we cover in more depth in the muscle-loss article linked above.

Who should not take these medications?

Both carry a boxed warning about thyroid C-cell tumors seen in rodents, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your full personal and family history is exactly what a licensed clinician needs to weigh before starting anything.

References

1. Kodoth V, Scaccia S, Aggarwal B (2022). Adverse Changes in Body Composition During the Menopausal Transition and Relation to Cardiovascular Risk: A Contemporary Review. Women's Health Reports, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC9258798/ (Accessed 2026-07-15).
2. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, via PubMed (National Library of Medicine). https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-15).
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, via PubMed (National Library of Medicine). https://pubmed.ncbi.nlm.nih.gov/35658024/ (Accessed 2026-07-15).
4. U.S. Food and Drug Administration / Novo Nordisk (2025). WEGOVY (semaglutide) injection, for subcutaneous use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564 (Accessed 2026-07-15).
5. U.S. Food and Drug Administration / Eli Lilly (2025). ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-15).
6. Tinsley GM, Nadolsky S (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medical Case Reports, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC12536186/ (Accessed 2026-07-15).